PTC Therapeutics, Inc. (NASDAQ:PTCT) CAO Christine Marie Utter Sells 1,291 Shares

PTC Therapeutics, Inc. (NASDAQ:PTCT) CAO Christine Marie Utter sold 1,291 shares of PTC Therapeutics stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $45.34, for a total transaction of $58,533.94. Following the completion of the sale, the chief accounting officer now owns 65,983 shares in the company, valued at approximately $2,991,669.22. This represents a 1.92 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Christine Marie Utter also recently made the following trade(s):

• On Monday, December 2nd, Christine Marie Utter sold 17,800 shares of PTC Therapeutics stock. The stock was sold at an average price of $51.77, for a total value of $921,506.00.

PTC Therapeutics Stock Down 2.4 %

Shares of PTCT traded down $1.10 during trading hours on Friday, reaching $43.94. 548,622 shares of the company traded hands, compared to its average volume of 529,154. PTC Therapeutics, Inc. has a 12-month low of $23.58 and a 12-month high of $54.16. The stock has a market capitalization of $3.39 billion, a P/E ratio of -7.40 and a beta of 0.62. The business has a fifty day moving average price of $45.12 and a 200-day moving average price of $38.39.

Institutional Investors Weigh In On PTC Therapeutics

Large investors have recently bought and sold shares of the company. KBC Group NV raised its stake in shares of PTC Therapeutics by 29.2% during the 3rd quarter. KBC Group NV now owns 2,232 shares of the biopharmaceutical company’s stock valued at $83,000 after buying an additional 504 shares during the last quarter. CWM LLC raised its stake in shares of PTC Therapeutics by 354.7% during the 3rd quarter. CWM LLC now owns 2,687 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 2,096 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in PTC Therapeutics by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,782 shares of the biopharmaceutical company’s stock worth $104,000 after acquiring an additional 492 shares during the period. Quest Partners LLC purchased a new position in PTC Therapeutics in the 2nd quarter valued at about $128,000. Finally, Quarry LP lifted its position in shares of PTC Therapeutics by 100.0% in the second quarter. Quarry LP now owns 5,000 shares of the biopharmaceutical company’s stock valued at $153,000 after acquiring an additional 2,500 shares in the last quarter.

Analyst Ratings Changes

Several analysts have recently issued reports on PTCT shares. Morgan Stanley upgraded shares of PTC Therapeutics from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $45.00 to $67.00 in a research report on Friday, December 13th. StockNews.com lowered shares of PTC Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Royal Bank of Canada raised PTC Therapeutics from a “sector perform” rating to an “outperform” rating and increased their price objective for the stock from $39.00 to $63.00 in a research note on Tuesday, December 3rd. Citigroup increased their target price on shares of PTC Therapeutics from $26.00 to $32.00 and gave the stock a “sell” rating in a report on Wednesday, December 4th. Finally, Raymond James started coverage on PTC Therapeutics in a report on Thursday, October 10th. They issued a “market perform” rating on the stock. Three analysts have rated the stock with a sell rating, four have assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $54.08.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.